MX2019010575A - Metodo para producir anticuerpos multiespecificos. - Google Patents

Metodo para producir anticuerpos multiespecificos.

Info

Publication number
MX2019010575A
MX2019010575A MX2019010575A MX2019010575A MX2019010575A MX 2019010575 A MX2019010575 A MX 2019010575A MX 2019010575 A MX2019010575 A MX 2019010575A MX 2019010575 A MX2019010575 A MX 2019010575A MX 2019010575 A MX2019010575 A MX 2019010575A
Authority
MX
Mexico
Prior art keywords
antibody
producing
multispecific antibodies
producing multispecific
cell
Prior art date
Application number
MX2019010575A
Other languages
English (en)
Inventor
Paul Wolfgang
Seeber Stefan
Kettenberger Hubert
Goepfert Ulrich
Osterlehner Andrea
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2019010575A publication Critical patent/MX2019010575A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency

Abstract

En la presente se proporciona un método para producir un anticuerpo multiespecífico que comprende las siguientes etapas: proporcionar una célula de mamífero que expresa el anticuerpo, transfectar la célula de mamífero con un vector de expresión que comprende un casete de expresión que codifica un polipéptido del anticuerpo que tiene un entrecruzamiento de dominios, cultivar la célula transfectada y recuperar el anticuerpo de la célula o del medio de cultivo y producir así el anticuerpo multiespecífico.
MX2019010575A 2017-03-10 2018-03-07 Metodo para producir anticuerpos multiespecificos. MX2019010575A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17160415 2017-03-10
PCT/EP2018/055532 WO2018162517A1 (en) 2017-03-10 2018-03-07 Method for producing multispecific antibodies

Publications (1)

Publication Number Publication Date
MX2019010575A true MX2019010575A (es) 2019-10-15

Family

ID=58266981

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010575A MX2019010575A (es) 2017-03-10 2018-03-07 Metodo para producir anticuerpos multiespecificos.

Country Status (18)

Country Link
US (2) US20200216553A1 (es)
EP (1) EP3592767A1 (es)
JP (2) JP7021245B2 (es)
KR (2) KR20190124270A (es)
CN (1) CN110402253B (es)
AU (1) AU2018232698B2 (es)
BR (1) BR112019016970A2 (es)
CA (1) CA3052357A1 (es)
CL (1) CL2019002521A1 (es)
CR (1) CR20190397A (es)
IL (1) IL268470A (es)
MA (1) MA48723A (es)
MX (1) MX2019010575A (es)
NZ (1) NZ756132A (es)
PE (1) PE20191360A1 (es)
RU (1) RU2750721C2 (es)
SG (1) SG11201908127WA (es)
WO (1) WO2018162517A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ741067A (en) * 2015-10-02 2023-07-28 Hoffmann La Roche Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
EP3947437A1 (en) 2019-03-29 2022-02-09 F. Hoffmann-La Roche AG Method for the generation of an fcrn expressing cell by targeted integration of multiple expression cassettes in a defined organization
CA3137457A1 (en) * 2019-05-07 2020-11-12 Amgen Inc. Vectors and expression systems for producing recombinant proteins
KR20220010549A (ko) 2019-06-19 2022-01-25 에프. 호프만-라 로슈 아게 정의된 조직에서 다중 발현 카세트의 표적화된 통합에 의해 다가 이중특이성 항체 발현 세포를 생성하는 방법
CA3140318A1 (en) 2019-06-19 2020-12-24 Johannes Auer Method for the generation of a bivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
MX2021015536A (es) 2019-06-19 2022-02-10 Hoffmann La Roche Metodo para la generacion de una celula que expresa proteina mediante integracion dirigida usando acido ribonucleico mensajero (arnm) de cre.
EP3986925A1 (en) 2019-06-19 2022-04-27 F. Hoffmann-La Roche AG Method for the generation of a trivalent antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
KR20220024636A (ko) 2019-06-19 2022-03-03 에프. 호프만-라 로슈 아게 정의된 조직의 다수 발현 카세트들의 표적화 통합에 의한 다가, 다중특이성 항체 발현 세포의 생성 방법

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4912038A (en) 1984-12-11 1990-03-27 California Biotechnology Inc. Recombinant DNA sequence encoding alveolar surfactant protein
DE3688418T2 (de) 1985-02-13 1993-08-26 Scios Nova Inc Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen.
US5550036A (en) 1986-04-09 1996-08-27 Eli Lilly And Company Method for co-amplification of human protein C genes in human cells
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
WO1989000605A1 (en) 1987-07-16 1989-01-26 Codon Transfected cells containing plasmids having genes oriented in opposing directions and methods of obtaining the same
CA1341235C (en) 1987-07-24 2001-05-22 Randy R. Robinson Modular assembly of antibody genes, antibodies prepared thereby and use
EP0319206A3 (en) 1987-11-30 1990-04-18 Berlex Laboratories, Inc. Gene amplification
WO1989010959A1 (en) 1988-05-06 1989-11-16 Codon Supertransformants for high expression rates in eukaryotic cells
DD287531A5 (de) 1988-06-16 1991-02-28 Akademie Der Wissenschaften,De Verfahren zur herstellung von humanem wachstumshormon (sth) in tierischen zellen
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
GB9114468D0 (en) 1991-07-04 1991-08-21 Wellcome Found Antibody production
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
EP0569678A3 (en) 1992-03-13 1994-10-26 Yeda Res & Dev Double transfectants of MHC genes as cellular vaccines for immunoprevention of tumor metastasis.
US6482919B2 (en) * 1993-02-01 2002-11-19 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5420019A (en) 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
DE69430824T2 (de) 1993-08-12 2003-01-23 Neurotech Sa Biokompatible immunoisolatorische Kapseln, die genetisch veränderte Zellen enthalten
WO1995017513A1 (en) 1993-12-23 1995-06-29 Novo Nordisk A/S Retransformation of filamentous fungi
US5719050A (en) 1993-12-24 1998-02-17 Eiken Chemical Co., Ltd. Animal cell culturing media containing N-acetyl-L-glutamic acid
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
WO1997008342A1 (en) 1995-08-30 1997-03-06 Gentest Corporation Cytochrome p450 reporter gene
WO1998008934A1 (en) 1996-08-30 1998-03-05 Life Technologies, Inc. Serum-free mammalian cell culture medium, and uses thereof
US5958727A (en) 1996-09-13 1999-09-28 Novo Nordisk Biotech, Inc Methods for modifying the production of a polypeptide
IL132560A0 (en) 1997-05-02 2001-03-19 Genentech Inc A method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
CA2310987A1 (en) 1997-11-26 1999-06-03 Eli Lilly And Company Tnf ligand family gene
CA2324518A1 (en) 1998-03-18 1999-09-23 Pharmacopeia, Inc. Eukaryotic cells stably expressing genes from multiple transfected episomes
BR9905867A (pt) 1998-11-06 2001-01-23 Bio Sidus S A Linhagem celular produtora de eritropoietina humana recombinante e a eritropoietina humana recombinante produzida por esta célula
TW570977B (en) 1998-12-07 2004-01-11 Li-Wei Hsu An expression system for producing recombinant human erythropoietin, method for purifying secreted human erythropoietin and uses thereof
DE19920712A1 (de) 1999-05-05 2000-11-09 Rhein Biotech Proz & Prod Gmbh Verfahren zum Herstellen eines rekombinanten Proteines
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
AUPQ422399A0 (en) 1999-11-24 1999-12-16 University Of New South Wales, The Method of screening transformed or transfected cells
LT2857516T (lt) 2000-04-11 2017-09-11 Genentech, Inc. Multivalentiniai antikūnai ir jų panaudojimas
JP2002027581A (ja) 2000-07-13 2002-01-25 Npl:Kk スピーカ
DE10036491A1 (de) 2000-07-25 2002-02-07 Roche Diagnostics Gmbh Expression von Alkalischer Phosphatase in Hefe
EP1383800A4 (en) * 2001-04-02 2004-09-22 Idec Pharma Corp RECOMBINANT ANTIBODIES CO-EXPRESSED WITH GNTIII
US20030157641A1 (en) * 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
CA2468832A1 (en) 2001-11-28 2003-06-05 Sandoz Gmbh Method for producing a recombinant polypeptide
EP1488234A4 (en) 2002-03-05 2006-05-24 Vitra Bioscience Inc TRANSFECTION OF MULTIPLEXED CELLS USING CODED MEDIA
DE10213201A1 (de) 2002-03-25 2003-10-16 Roche Diagnostics Gmbh Erzeugung von schwach aktiven oder inaktiven Mutanten von Alkalischer Phosphatase und deren Expression in Hefe
US20050266425A1 (en) * 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
WO2005113770A1 (en) 2004-05-13 2005-12-01 Institut Gustave Roussy Anti-rhoa and -rhoc sirnas and therapeutic compositions comprising them.
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
DE102005046225B4 (de) 2005-09-28 2012-01-05 Cellca Gmbh Verbessertes Zellkulturmedium
AU2007229698B9 (en) 2006-03-24 2012-11-08 Merck Patent Gmbh Engineered heterodimeric protein domains
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
CA2709847C (en) 2008-01-07 2018-07-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
JP2012525149A (ja) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
JP5856073B2 (ja) 2009-12-29 2016-02-09 エマージェント プロダクト デベロップメント シアトル， エルエルシー Ｒｏｎ結合構築体およびその使用方法
CA2797981C (en) 2010-05-14 2019-04-23 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
ES2537207T3 (es) * 2010-08-16 2015-06-03 Novimmune S.A. Métodos para la generación de anticuerpos multiespecíficos y multivalentes
DK2635607T3 (da) 2010-11-05 2019-11-18 Zymeworks Inc Stabilt heterodimert antistofdesign med mutationer i fc-domænet
US10150968B2 (en) * 2011-08-19 2018-12-11 Alderbio Holdings Llc Multi-copy strategy for high-titer and high-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
HUE038225T2 (hu) 2011-08-23 2018-10-29 Roche Glycart Ag Bispecifikus, T-sejtaktiváló antigénkötõ, molekulák
RS60499B1 (sr) 2011-12-20 2020-08-31 Medimmune Llc Modifikovani polipeptidi za bispecifične skelete antitela
SG10201607371UA (en) 2012-04-20 2016-10-28 Merus Nv Methods and means for the production of ig-like molecules
RU2646159C2 (ru) * 2012-09-14 2018-03-01 Ф. Хоффманн-Ля Рош Аг Способ получения и отбора молекул, включающих по меньшей мере две различные группировки, и их применение
SG11201504497TA (en) 2013-02-26 2015-09-29 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
EP2970485A1 (en) * 2013-03-15 2016-01-20 Merck Patent GmbH Tetravalent bispecific antibodies
WO2015052230A1 (en) 2013-10-11 2015-04-16 F. Hoffmann-La Roche Ag Multispecific domain exchanged common variable light chain antibodies
PL3092251T3 (pl) 2014-01-06 2021-08-02 F. Hoffmann-La Roche Ag Jednowartościowe moduły transportera wahadłowego przez barierę krew-mózg
WO2016016299A1 (en) * 2014-07-29 2016-02-04 F. Hoffmann-La Roche Ag Multispecific antibodies
EP3204412B1 (en) 2014-10-08 2020-08-19 F.Hoffmann-La Roche Ag Combination therapy of bispecific antibodies specific for fap and dr5 and chemotherapeutic agents
AR106189A1 (es) * 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
NZ741067A (en) 2015-10-02 2023-07-28 Hoffmann La Roche Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
MY192202A (en) 2015-10-02 2022-08-06 Hoffmann La Roche Bispecific antibodies specific for pd1 and tim3

Also Published As

Publication number Publication date
SG11201908127WA (en) 2019-10-30
EP3592767A1 (en) 2020-01-15
AU2018232698B2 (en) 2020-06-25
JP2022001059A (ja) 2022-01-06
KR20190124270A (ko) 2019-11-04
WO2018162517A1 (en) 2018-09-13
US20200216553A1 (en) 2020-07-09
JP2020509754A (ja) 2020-04-02
MA48723A (fr) 2020-04-08
NZ756132A (en) 2022-02-25
BR112019016970A2 (pt) 2020-04-07
IL268470A (en) 2019-09-26
US20230129340A1 (en) 2023-04-27
CA3052357A1 (en) 2018-09-13
CN110402253B (zh) 2024-01-05
CN110402253A (zh) 2019-11-01
CL2019002521A1 (es) 2020-01-31
KR20210132207A (ko) 2021-11-03
RU2019131113A (ru) 2021-04-12
RU2750721C2 (ru) 2021-07-01
PE20191360A1 (es) 2019-10-01
RU2019131113A3 (es) 2021-04-12
JP7021245B2 (ja) 2022-02-16
AU2018232698A1 (en) 2019-08-15
CR20190397A (es) 2019-09-27

Similar Documents

Publication Publication Date Title
MX2019010575A (es) Metodo para producir anticuerpos multiespecificos.
WO2018081789A8 (en) Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion
ZA202000027B (en) Constructs specifically recognizing glypican 3 and uses thereof
MX2020013977A (es) Proteínas quiméricas transmembrana y usos de las mismas.
SG10201900323SA (en) Method for inducing t cells for cell-based immunotherapy from pluripotent stem cells
MX2020010235A (es) Vectores de expresion para receptores de engullimiento quimerico, celulas hospederas geneticamente modificadas y usos de los mismos.
MY195442A (en) Anti-CD40 Antibodies and Their Uses
MY189778A (en) Method for producing retinal pigment epithelial cells
MX2019003427A (es) Composiciones para cultivo celular y metodos para la produccion de polipeptidos.
MX2021000459A (es) Metodo para producir celulas t gamma y delta.
MX2018015298A (es) Metodo para estabilizar proteinas.
IL284382A (en) Anti-4 CTLA antibodies, vectors and cells containing them and methods for their production
PH12016501689A1 (en) Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof
MX2017011220A (es) Metodos para hacer celulas madre neurales y usos de las mismas.
BR112019016672A8 (pt) Método para gerar progenitores de células t
EP3770248A4 (en) CELL CULTURE METHOD, CELL SUPPORT COMPOSITE PRODUCTION METHOD, CULTURED CELLS AND CELL SUPPORT COMPOSITE
MX2021003219A (es) Biomaterial que comprende celulas germinales derivadas de tejido adiposo y gelatina y metodo para producir el mismo.
MY178060A (en) Methods of preparing a poloxamer for use in cell culture medium
WO2019036043A3 (en) METHOD FOR GENERATING A COCKTAIL OF PERSONALIZED ANTICANCER VACCINES FROM TUMOR DERIVED GENETIC MODIFICATIONS FOR THE TREATMENT OF CANCER
NZ729729A (en) Production of fully processed and functional factor x in a furin-secreting mammalian expression system
MX2018016417A (es) Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de las mismas.
AU2017248848A1 (en) Enhanced gene delivery methods
MX2018003445A (es) Expresion de proteinas que contienen fc.
WO2019070435A8 (en) Methods for selectively expanding cells expressing a tcr with a murine constant region
PH12019501765A1 (en) Factor ix fusion proteins and methods of making and using same